Bayer Healthcare Pharmaceuticals has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents for cancer drug Stivarga (regorafenib).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
10 September 2026 Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.
7 September 2026 A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.
27 August 2026 Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.
